Iovance Biotherapeutics (IOVA) Expected to Post Earnings on Thursday

Iovance Biotherapeutics (NASDAQ:IOVA) is projected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Iovance Biotherapeutics to announce earnings of ($0.0841) per share and revenue of $115.53 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. The company had revenue of $99.31 million during the quarter, compared to the consensus estimate of $87.83 million. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The firm’s revenue was up 65.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.33) earnings per share. On average, analysts expect Iovance Biotherapeutics to post ($0.45) EPS for the current fiscal year and ($0.22) EPS for the next fiscal year.

Iovance Biotherapeutics Trading Down 5.4%

IOVA opened at $8.02 on Tuesday. The stock has a market capitalization of $3.63 billion, a P/E ratio of -10.99 and a beta of 0.76. Iovance Biotherapeutics has a 12 month low of $1.76 and a 12 month high of $15.37. The firm’s fifty day simple moving average is $11.37 and its 200 day simple moving average is $5.85.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. UBS Group increased their price objective on Iovance Biotherapeutics from $4.00 to $7.00 and gave the stock a “neutral” rating in a report on Thursday, August 20th. Citigroup restated an “outperform” rating on shares of Iovance Biotherapeutics in a research note on Friday, August 7th. HC Wainwright upped their price target on Iovance Biotherapeutics from $9.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, September 29th. Robert W. Baird upped their price target on Iovance Biotherapeutics from $6.00 to $11.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Finally, TD Cowen lifted their price objective on shares of Iovance Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Iovance Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $13.20.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.